Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer - BeOne

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

BeOne Study ID

AdvanTIG-204

ClinicalTrials.gov ID

NCT04952597

China Drug Trials ID

CTR20211531

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan